Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that CEO Pete Salzmann will participate in a fireside chat at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat is scheduled for September 14 at 4:00 PM Eastern Time. Interested parties can access the presentation via a webcast on the company’s website. Immunovant is developing innovative therapies, including the investigational compound batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was -1.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022.
H.C. Wainwright Global Investment Conference fireside chat details:
| Date: | Thursday, September 14th, 2022 |
| Time: | 4:00 pm Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.